The next 12 months could look very different from the past year for this biotech company.
Compare CRSP Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: CRISPR Therapeutics
They are also outperforming the S&P 500.
These companies have become great deals because of the market downturn.
These stocks are losers now. But they could be huge winners over the next few years.
This company's targeting a market with explosive growth.
The only thing standing in the way is the clinical trials process, which takes time and patience.
It's been a tough past 12 months for this gene-editing specialist.
The biotech stock is making gains despite market pressures, but it's still down roughly 71% from its high.
Recent comments from the company's CEO are prompting bullish momentum for the stock.
Despite big gains today, the biotech specialist's share price is still down roughly 46% over the past year of trading.